Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.50 |
| ▸ | CTSL | P07711 | 6/20 | 0.50 |
| ▸ | CTSV | O60911 | 5/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451610 | 0.94 | CTSS (0.55) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL7014847 | 0.91 | CTSK (0.44) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL7017832 | 0.91 | RAB9A (0.45) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL4451291 | 0.90 | CTSK (0.56) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL7020885 | 0.89 | CTSK (0.43) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL4457938 | 0.89 | CTSS (0.47) | CTSSCTSLCTSVCTSK | |
| SCHEMBL7014652 | 0.89 | CTSK (0.44) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL7016550 | 0.87 | CTSK (0.41) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL4459397 | 0.87 | DPP4 (0.49) | CTSSCTSLCTSVCTSKDPP4 | |
| SCHEMBL4457853 | 0.86 | PREP (0.47) | CTSSCTSLCTSVCTSKDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-7425562-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD. (GB) | 2008-09-16 | — | — | US | disclosed |
| EP-1362052-B1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 39/4885CTSL 23/4885CTSV 27/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | CTSS 21/4885CTSL 16/4885CTSV 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.